Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $41.00 Consensus PT from Analysts

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) have earned an average recommendation of “Moderate Buy” from the five brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $41.00.

A number of analysts have commented on ELVN shares. Wall Street Zen downgraded shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, January 21st.

Insider Buying and Selling

In other news, CFO Benjamin Hohl sold 10,000 shares of the business’s stock in a transaction dated Friday, March 6th. The shares were sold at an average price of $29.58, for a total transaction of $295,800.00. Following the transaction, the chief financial officer owned 51,000 shares of the company’s stock, valued at approximately $1,508,580. The trade was a 16.39% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Richard A. Heyman sold 9,635 shares of the company’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $25.03, for a total transaction of $241,164.05. Following the completion of the sale, the director directly owned 25,545 shares of the company’s stock, valued at $639,391.35. This represents a 27.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 232,180 shares of company stock worth $6,217,033. 25.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Enliven Therapeutics

Several hedge funds have recently made changes to their positions in ELVN. Seven Fleet Capital Management LP acquired a new stake in shares of Enliven Therapeutics during the 4th quarter worth approximately $180,000. Invesco Ltd. lifted its holdings in Enliven Therapeutics by 7.0% in the fourth quarter. Invesco Ltd. now owns 24,720 shares of the company’s stock valued at $381,000 after acquiring an additional 1,624 shares during the last quarter. XTX Topco Ltd lifted its holdings in Enliven Therapeutics by 472.6% in the fourth quarter. XTX Topco Ltd now owns 60,702 shares of the company’s stock valued at $935,000 after acquiring an additional 50,101 shares during the last quarter. Vestal Point Capital LP grew its position in Enliven Therapeutics by 230.2% in the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after acquiring an additional 2,670,000 shares during the period. Finally, Virtus Investment Advisers LLC grew its position in Enliven Therapeutics by 172.6% in the fourth quarter. Virtus Investment Advisers LLC now owns 15,778 shares of the company’s stock worth $243,000 after acquiring an additional 9,991 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Stock Down 3.6%

Shares of ELVN opened at $28.96 on Wednesday. Enliven Therapeutics has a 52-week low of $13.30 and a 52-week high of $31.75. The firm’s fifty day moving average is $27.63 and its two-hundred day moving average is $22.46. The stock has a market cap of $1.73 billion, a PE ratio of -15.57 and a beta of 0.33.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). As a group, research analysts anticipate that Enliven Therapeutics will post -1.95 earnings per share for the current year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.